A recent study shows that CK2 pharmacological inhibition reduces the accumulation of tau in vitro, but whether these effects are mediated by SET exclusion from the cytosol and whether this inhibition would ameliorate AD symptoms in vivo is not known [136]. This evidence concerns the gene MAPT and Alzheimer disease.